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revealed remarkable GR-dependent cooperation between CpdA
and Bortezomib in suppressing survival of lymphoma cells
in vitro and in vivo. Also surprising findings were substantial
cooperation in anti-cancer effect of immunosuppressant Rapa-
mycin and CpdA in vitro, and unexpected ‘‘dissociated” effect of
Rapamycin on GR signaling realized through down -regulation
of REDD1, mTORC1 inhibitor. These data suggested high clinical
potential of Rapamycin/GC combination in cancer treatment.
(2) SEGRA list extention
We used two approaches to extend SEGRA list: (1) synthesis of
CpdA enantiomers and (2) its chemical derivatives. Chemical
analogues of CpdA were designed by appending of bulky sub-
stituent into benzene ring, alkylation of carbon atom adjacent
to chlorine atom or appending of substituents to nitrogen atom.
Evaluation of biological properties of enantiomers revealed
higher GR-dependent anti-cancer potential of S-CpdA. Cytotoxic
and proapoptotic effects of CpdA analogues were comparable
with precursor.
(3) Selection of tumor types acceptable for SEGRA treatment.
CpdAwas selected for NCI-60 in Vitro Cell Line Screening Pro-
ject providing direct support to anticancer drug discovery pro-
gram. It was shown that CpdA affect viability of some adherent
cancer cell lines. We demonstrated that CpdA unlike GCs did
not modify microenvironment and disintegrate tight junctions
between cells decreasing risk of metastasis in case of solid
tumors. It demonstrates reasonability of further investigations.
Overall, our data provide the rationale for novel therapy of
cancer based on combination of non-steroidal GR modulators
with classic and modern chemotherapeutics. Approaches to
obtain more SEGRAs were elaborated.
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Background: There are numerous evidences suggesting that
tumor evolution follows the laws of Darwinian evolution,
whereby individual tumor cell clones have private genetic
aberrations, including chromosomal abnormalities. The
combined effect of genetic instability and differential selective
pressures of the microenvironment and chemotherapy can result
in the creation of new tumor clones (Navin et al., 2011; Ng et al.,
2012). The aim of this study is to show breast tumor clonal evolu-
tion during neoadjuvant chemotherapy (NAC) using microarray
analysis.
Material and methods: Breast cancer patients (n = 26) with
stage IIA to IIIC (T1-4N0-3M0), were treated with NAC (FAC or
CAX regimens). DNA was extracted from 26 samples of tumor
tissue derived before or after NAC using QIAamp DNA mini Kit
(Qiagen, Germany). Copy Number Aberrations (CNA, deletions
and amplifications, or Loss and Gain, respectively) and number
of mutant clones were detected in pre- and post-NAC tumor
samples using the high density microarray platform Affymetrix
(USA) CytoScanTM HD Array. This study was approved by Tomsk
Cancer Research Institute review board.
Results: We have revealed that 19% (5/26) of patients during the
NACshowed thedecrease in thenumberofmutant clones andCNA
frequency right up to their complete elimination (genetic
regression) at one case. In 7 (27%) cases chemotherapy had no
any effect on number of mutant clones and the frequency of CNA
in tumor. In the tumors of 10 patients the elimination of some
mutant clones aswell as the formation of new cloneswith deleted
genetic material occurred under the influence of chemotherapy. 6
patients have demonstrated the appearance of new tumor clones
with gene amplificationswhich were associatedwith the develop-
ment of metastases in 83% of cases (5/6). All other patients (n = 21)
who has not acquired the new tumor clones with Gain function
mutation after NAC did not manifest distant metastasis in 5-year
follow-up (Kaplan–Meier, p = 0.00001 Log-rank test).
Conclusion: The first time evidence is presented that the for-
mation of new tumor clones may occur during the NAC. Metasta-
sis of breast cancer is associated with the appearance of new
clones with DNA amplifications. Detection of these clones allow
getting new prognostic factor in breast cancer.
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Cutaneous melanoma is one of the most aggressive human
neoplasms that can quickly metastasize to regional lymph nodes.
Currently, prognosis is determined by measuring tumor thickness
but more reliable markers for metastatic spread are urgently
needed. It is well known that tumors require a microvasculature
development in order to grow and metastasize. Angiogenesis
and lymphangiogenesis play an important role not only in the
tumor growth, but also in the tumor metastasis. As malignancy
is a disorder of cellular growth control, the assessment of cell
proliferation rates in tumors has intuitive appeal as a prognostic
marker. One such biomarker is Ki-67, a cell cycle dependent
protein. Recent reports related to its role as a prognostic factor
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